Periodontal Diseases
Conditions
Brief summary
This is a multi-center, randomized, double-blinded, placebo-controlled study to evaluated the efficacy and safety of DKF-306 in patients with periodontal diseases.
Interventions
DRUGDKF-306
Active ingredients
DRUGPlacebo
Placebo
Sponsors
Dongkook Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Aged 19 years and older * Periodontal diseases * Having not less than 16 permanent teeth including at least 4 molars (third molars excluded) * Having teeth with not less than 2 sites of both probing pocket depth (PPD) ≥ 4 mm and gingival index (GI) ≥ 2 in at least 2 quadrants * Agrees not to use over-the-counters (oral, ointment, toothpaste, film, etc.) or quasi-drugs (gargle and mouthwash) to alleviate or treat the symptoms of gingivitis or periodontitis during the study * Voluntarily signed the informed consent form * Willing to participate in the study
Exclusion criteria
* Hypersensitivity to ingredients of investigational products * Hypersensitivity to Azo dyes, acetylsalicylic acid or other prostaglandin synthase inhibitors * Following diseases or state in the mouth: 1. rampant caries or decayed tooth/teeth remained untreated for a long time 2. multiple restorations which may be related to periodontal inflammation 3. poor oral hygiene with heavy plaque or calculus deposition 4. soft or hard tissue tumor 5. systemic chronic diseases with oral manifestations 6. fibrotic gingival enlargement * Use of orthodontic appliances or removable partial denture(s) * Having teeth or state in need of immediate treatment such as periodontal abscess, a tooth indicated for extraction, etc. * History of aggressive periodontitis or acute necrotizing ulcerative gingivitis * Received dental treatments such as endodontic treatments or periodontal therapy (including both nonsurgical and surgical therapy) within 3 months from randomization * Received the following drugs for more than 2 weeks within 3 months from randomization: 1. systemic/local antibiotics in the mouth or non-steroidal anti-inflammatory drugs 2. cyclosporine or corticosteroids 3. phenytoin, calcium antagonists, anticoagulants or antiplatelets * Initiated drugs in treatment of chronic diseases within 3 months from randomization * Received the same drug with investigational products within 3 months from randomization * Medical conditions or diseases affecting the efficacy and safety of investigational products at the investigator's discretion * Heavy smoker (20 cigarettes or more a day) * Pregnant or breast-feeding * Plans to have a child or unwilling to comply with using medically accepted contraception methods during the study * Alcohol or drug abuse * Other investigational products or procedures within 3 months from screening * Not eligible due to other reasons at the investigator's discretion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in gingival index from baseline to Week 12 | Weeks 0 and 12 |
Secondary
| Measure | Time frame |
|---|---|
| Change in plaque index from baseline to Weeks 4, 8 and 12 | Weeks 0, 4, 8 and 12 |
| Change in probing pocket depth from baseline to Weeks 4, 8 and 12 | Weeks 0, 4, 8 and 12 |
| Change in clinical attachment level from baseline to Weeks 4, 8 and 12 | Weeks 0, 4, 8 and 12 |
| Change in bleeding on probing (%) from baseline to Weeks 4, 8 and 12 | Weeks 0, 4, 8 and 12 |
| Change in gingival index from baseline to Weeks 4 and 8 | Weeks 0, 4 and 8 |
Countries
South Korea
Contacts
Primary ContactYoung-Sung Kim
Outcome results
None listed